Recent director dealings and insider transactions at Edwards Lifesciences Corporation (EW),
from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
Date
Insider
Type
Shares
2026-07-30
Markowitz Wayne
SELL
146
2026-07-28
Markowitz Wayne
SELL
9,628
2026-07-28
Markowitz Wayne
SELL
9,628
2026-07-28
Markowitz Wayne
BUY
9,628
2026-07-11
Bruls Annette
SELL
109
2026-07-10
Lippis Daniel J.
SELL
619
2026-07-10
Lippis Daniel J.
SELL
619
2026-07-10
Lippis Daniel J.
BUY
619
2026-07-09
Mistras Theodora
BUY
12,325
2026-07-09
Mistras Theodora
BUY
61,800
Graham NCAV AnalysisAbove net-net level
Current Assets$6.74B
Less: Total Liabilities−$3.36B
= Net Current Asset Value$3.38B
NCAV Per Share$5.1303
Current Price$83.68
Price / NCAV16.31×
Margin of Safety-1531.1%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.855
Dividend/yrNone
52W High$96.29
52W Low$72.30
52-Week Range
$72.30Now$96.29
69% through annual range
From 52W High−7.8%
From 52W Low+22.8%
📖 Plain English Summary
Edwards Lifesciences Corporation is at 69% of its 52-week range. Beta 0.855 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for EW🟢 Bullish⬜ Neutral🔴 Bearish
🤖
DipBuster AI Analysis — EW
Heuristic · balance sheet, insider filings, price data, academic research
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With …